Difference between revisions of "Peginterferon alfa-2a (Pegasys)"
m (→References) |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Chronic myelogenous leukemia]] | *[[Chronic myelogenous leukemia]] | ||
| + | *[[Essential thrombocythemia]] | ||
*[[Hypereosinophilic syndrome]] | *[[Hypereosinophilic syndrome]] | ||
| + | *[[Polycythemia vera]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *10/16/2002: Initial FDA approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa. | ||
==References== | ==References== | ||
| Line 21: | Line 26: | ||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
| + | [[Category:Essential thrombocythemia medications]] | ||
[[Category:Hypereosinophilic syndrome medications]] | [[Category:Hypereosinophilic syndrome medications]] | ||
| + | [[Category:Polycythemia vera medications]] | ||
[[Category:Drugs FDA approved in 2002]] | [[Category:Drugs FDA approved in 2002]] | ||
Revision as of 14:10, 17 September 2015
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to Interferon alfa-2a (Roferon-A).[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 10/16/2002: Initial FDA approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa.